SANTA MONICA, Calif. and LAS VEGAS, July 10 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), one of the largest umbilical cord blood stem cell preservation companies (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today it has hired famed Immunologist Dr. Geoffrey John O'Neill as its new Laboratory Director and Brian Pockett as Vice President of Laboratory Operations.
Cord Blood America recently announced it is opening a state-of-the-art laboratory for the storage of multiple stem cell products, including umbilical cord blood stem cells, in Las Vegas, Nevada.
"We are pleased that two such distinguished, experienced, successful professionals will be overseeing our new lab," said Company founder and CEO Matthew Schissler. "The lab will be used to process and store umbilical cord blood stem cells, to store other forms of stem cells such as peripheral blood stem cell and adipose tissues, and for research and product development."
Dr. O'Neill was Laboratory and Scientific/Medical Director for Cryo-Cell International Inc. in Florida and was Laboratory Director for the Bio-Matrix Scientific Group Inc., a San Diego biotech research and development firm in the stem cell sector. He received a Ph.D. in Immunology from the
Mr. Pockett has more than 30 years professional experience in operations, business development, marketing, sales and financial and grant development. He has served as a consultant on global distribution, product development, commercialization, investment and intellectual properties for some of the largest companies in the U.S. He also served as Managing Director and Chief Operating Officer for Bio-Matrix Scientific Group Inc.
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 email@example.com
|SOURCE Cord Blood America, Inc.|
Copyright©2009 PR Newswire.
All rights reserved